TRTessel Meike van Rossen

Tessel Meike van Rossen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tessel Meike van Rossen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Andries E. Budding

    InBiome, Amsterdam, The Netherlands

    4 shared publications
  • Christina M.J.E. Vandenbroucke-Grauls

    Department of Medical Microbiology & Infection Control, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

    3 shared publications
  • Christina Maria Joseph Elisabeth Vandenbroucke-Grauls

    Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands

    3 shared publications
  • Ed J. Kuijper

    Leiden University Medical Center, Center for Infectious Diseases, Medical Microbiology, Leiden, The Netherlands

    3 shared publications
  • Joffrey van Prehn

    Leiden University Medical Center, Center for Infectious Diseases, Medical Microbiology, Leiden, The Netherlands

    3 shared publications
  • Marcel Jonges

    Department of Medical Microbiology and Infection Control, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, PK 2X132, De Boelelaan 1117, Amsterdam, The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Comparison of microbiota profiles of fecal samples, rectal swabs and mucosal biopsies in patients with inflammatory bowel disease

    by Tessel M. van Rossen, Kim van Den Hoek, Thomas Groot, Rob H. Creemers, Maysa L. M. van Doorn-Schepens, Emma M. van Andel, Matthijs E. Grasman, Nanne K. H. de Boer, Gerd Bouma, Andries E. Budding, et al.

    Gut microbiota changes are associated with inflammatory bowel disease (IBD). In most microbiota studies, intestinal microbiota composition is examined in fecal samples, but their representativeness of mucosa-associated microbiota at inflammation sites remains unclear. This study aimed to explore microbiota composition in different IBD sample types and assess their interchangeability for research and clinical use. Multicentre, prospective, observational study including 200 IBD patients (518 samples). We compared microbiota profiles from faeces, rectal swabs and mucosal biopsies from different colon sites. Microbiota composition was analyzed by Molecular Culture™, a bacterial profiling technique based on species-specific differences in the 16S-23S interspace region of bacterial ribosomal DNA, with taxonomic classification by phylum-specific fluorescent PCR primers. Fecal samples and rectal swabs contained a higher microbial diversity and abundance than colonic biopsies. Microbiota compositions of different sample types within an individual happened to be quite dissimilar (median cosine similarities 0.43–0.53). Within individuals, biopsies from the same location in the colon were just as similar as biopsies from different locations (median cosine similarities 0.85 vs. 0.82, respectively). Fecal samples, rectal swabs and colonic biopsies of an individual show distinct microbiota profiles and should not be used interchangeably in microbiota studies or clinical applications.


  • Open Access

    Fecal microbiota composition is a better predictor of recurrent Clostridioides difficile infection than clinical factors in a prospective, multicentre cohort study

    by Tessel M. van Rossen, Yvette H. van Beurden, Johannes A. Bogaards, Andries E. Budding, Chris J.J. Mulder, Christina M.J.E. Vandenbroucke-Grauls

    Introduction: Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhoea. Fidaxomicin and fecal microbiota transplantation (FMT) are effective, but expensive therapies to treat recurrent CDI (reCDI). Our objective was to develop a prediction model for reCDI based on the gut microbiota composition and clinical characteristics, to identify patients who could benefit from early treatment with fidaxomicin or FMT. Methods: Multicentre, prospective, observational study in adult patients diagnosed with a primary episode of CDI. Fecal samples and clinical data were collected prior to, and after 5 days of CDI treatment. Follow-up duration was 8 weeks. Microbiota composition was analysed by IS-pro, a bacterial profiling technique based on phylum- and species-specific differences in the 16–23 S interspace regions of ribosomal DNA. Bayesian additive regression trees (BART) and adaptive group-regularized logistic ridge regression (AGRR) were used to construct prediction models for reCDI. Results: 209 patients were included, of which 25% developed reCDI. Variables related to microbiota composition provided better prediction of reCDI and were preferentially selected over clinical factors in joint prediction models. Bacteroidetes abundance and diversity after start of CDI treatment, and the increase in Proteobacteria diversity relative to baseline, were the most robust predictors of reCDI. The sensitivity and specificity of a BART model including these factors were 95% and 78%, but these dropped to 67% and 62% in out-of-sample prediction. Conclusion: Early microbiota response to CDI treatment is a better predictor of reCDI than clinical prognostic factors, but not yet sufficient enough to predict reCDI in daily practice.


  • Open Access

    Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review

    by Tessel M. van Rossen, Rogier E. Ooijevaar, Christina M.J.E. Vandenbroucke-Grauls, Olaf M. Dekkers, Ed J. Kuijper, Josbert J. Keller, Joffrey van Prehn


  • Open Access

    Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review

    by Victor D Plat, Tessel M van Rossen, Freek Daams, Nanne K de Boer, Tim G J de Meij, Andries E Budding, Christina M J E Vandenbroucke-Grauls, Donald L van der Peet

    Background: The role of esophageal microbiota in esophageal cancer treatment is gaining renewed interest, largely driven by novel DNA-based microbiota analysis techniques. The aim of this systematic review is to provide an overview of current literature on the possible association between esophageal microbiota and outcome of esophageal cancer treatment, including tumor response to (neo)adjuvant chemo(radio)therapy, short-term surgery-related complications, and long-term oncological outcome. Methods: A systematic review of literature was performed, bibliographic databases were searched and relevant articles were selected by two independent researchers. The Newcastle-Ottawa scale was used to estimate the quality of included studies. Results: The search yielded 1303 articles, after selection and cross-referencing, five articles were included for qualitative synthesis and four studies were considered of good quality. Two articles addressed tumor response to neoadjuvant chemotherapy and described a correlation between high intratumoral Fusobacterium nucleatum levels and a poor response. One study assessed surgery-related complications, in which no direct association between esophageal microbiota and occurrence of complications was observed. Three studies described a correlation between shortened survival and high levels of intratumoral F. nucleatum, a low abundance of Proteobacteria and high abundances of Prevotella and Streptococcus species. Conclusions: Current evidence points towards an association between esophageal microbiota and outcome of esophageal cancer treatment and justifies further research. Whether screening of the individual esophageal microbiota can be used to identify and select patients with a predisposition for adverse outcome needs to be further investigated. This could lead to the development of microbiota-based interventions to optimize esophageal microbiota composition, thereby improving outcome of patients with esophageal cancer.


  • Open Access

    Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls

    by Tessel M. van Rossen, Rogier E. Ooijevaar, Johan Ph. Kuyvenhoven, Anat Eck, Herman Bril, René Buijsman, Marja A. Boermeester, Hein B. A. C. Stockmann, Niels de Korte, Andries E. Budding

    Introduction: The etiology of diverticulosis is still poorly understood. However, in patients with diverticulitis, markers of mucosal inflammation and microbiota alterations have been found. The aim of this study was to evaluate potential differences of the gut microbiota composition and mucosal immunity between patients with asymptomatic diverticulosis and controls. Methods: We performed a prospective study on patients who underwent routine colonoscopy for causes not related to diverticular disease or inflammatory bowel disease. Participants were grouped based on the presence or absence of diverticula. Mucosal biopsies were obtained from the sigmoid and transverse colon. Microbiota composition was analyzed with IS-pro, a 16S-23S based bacterial profiling technique. To predict if patients belonged to the asymptomatic diverticulosis or control group a partial least squares discriminant analysis (PLS-DA) regression model was used. Inflammation was assessed by neutrophil and lymphocyte counts within the taken biopsies. Results: Forty-three patients were enrolled. Intestinal microbiota profiles were highly similar within individuals for all phyla. Between individuals, microbiota profiles differed substantially but regardless of the presence (n = 19) of absence (n = 24) of diverticula. Microbiota diversity in both sigmoid and transverse colon was similar in all participants. We were not able to differentiate between diverticulosis patients and controls with a PLS-DA model. Mucosal lymphocyte counts were comparable among both groups; no neutrophils were detected in any of the studied biopsies. Conclusions: Microbiota composition and inflammatory markers were comparable among asymptomatic diverticulosis patients and controls. This suggests that the gut microbiota and mucosal inflammation do not play a major role in the pathogenesis of diverticula formation.


  • Open Access

    GRADING prognostic factors for severe and recurrent Clostridioides difficile infection: expected and unexpected findings. A systematic review

    by Tessel M. van Rossen, Rogier E. Ooijevaar, Christina M.J.E. Vandenbroucke-Grauls, Olaf M. Dekkers, Ed. J. Kuijper, Josbert J. Keller, Joffrey van Prehn

    Background: Clostridioides difficile infection (CDI), its subsequent recurrences (rCDI), and severe CDI (sCDI) provide a significant burden for both patients and the healthcare system. Treatment consists of oral antibiotics. Fidaxomicin, bezlotoxumab and fecal microbiota transplantion (FMT) reduce the number of recurrences compared to vancomycin, but are more costly. Identifying patients diagnosed with initial CDI who are at increased risk of developing sCDI/rCDI could lead to more cost-effective therapeutic choices. Objectives: In this systematic review we aimed to identify clinical prognostic factors associated with an increased risk of developing sCDI or rCDI. Methods: PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched from database inception through March, 2021. Study selection was performed by two independent reviewers on the basis of predefined selection criteria; conflicts were resolved by consensus. Cohort and case-control studies providing an analysis of clinical or laboratory data to predict sCDI/rCDI in patients ≥18 years diagnosed with CDI, were included. Risk of bias was assessed with the Quality in Prognostic Research (QUIPS) tool and the quality of evidence by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, modified for prognostic studies. Overview tables of prognostic factors were constructed to assess the number of studies and the respective direction of an association (positive, negative, or no association). Results and conclusions: 136 studies were included for final analysis. Higher age and the presence of multiple comorbidities were prognostic factors for sCDI. Identified risk factors for rCDI were higher age, healthcare-associated CDI, prior hospitalization, PPIs started during/after CDI diagnosis and previous rCDI. Some variables that were found as risk factors for sCDI/rCDI in previous reviews were not confirmed in the current review, which can be attributed to differences in methodology. Risk stratification for sCDI/rCDI may contribute to a more personalized and optimal treatment for patients with CDI.


  • Open Access

    Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samples

    by Tessel M. van Rossen, Joffrey van Prehn, Alex Koek, Marcel Jonges, Robin van Houdt, Rosa van Mansfeld, Ed J. Kuijper, Christina M. J. E. Vandenbroucke-Grauls, Andries E. Budding

    Background: Clostridioides difficile is the most common cause of nosocomial diarrhea. Ribotyping of cultured strains by a PCR-based test is used to study potential transmission between patients. We aimed to develop a rapid test that can be applied directly on fecal samples for simultaneous detection and ribotyping of C. difficile, as well as detection of toxin genes. Methods: We developed a highly specific and sensitive primer set for simultaneous detection and ribotyping of C. difficile directly on total fecal DNA. Toxin genes were detected with primers adapted from Persson et al. (Clin Microbiol Infect 14(11):1057–1064). Our study set comprised 130 fecal samples: 65 samples with positive qPCR for C. difficile toxin A/B genes and 65 C. difficile qPCR negative samples. PCR products were analyzed by capillary gel electrophoresis. Results: Ribosomal DNA fragment peak profiles and toxin genes were detected in all 65 C. difficile positive fecal samples and in none of the 65 C. difficile negative samples. The 65 samples were assigned to 27 ribotypes by the Dutch reference laboratory. Our peak profiles corresponded to these ribotypes, except for two samples. During a C. difficile outbreak, patients were correctly allocated to the outbreak-cluster based on the results of direct fecal ribotyping, before C. difficile isolates were cultured and conventionally typed. Conclusion: C. difficile ribotyping directly on fecal DNA is feasible, with sensitivity and specificity comparable to that of diagnostic toxin gene qPCR and with ribotype assignment similar to that obtained by conventional typing on DNA from cultured isolates. This supports simultaneous diagnosis and typing to recognize an outbreak.


  • Open Access

    External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection

    by Tessel M. van Rossen, Laura J. van Dijk, Martijn W. Heymans, Olaf M. Dekkers, Christina M. J. E. Vandenbroucke-Grauls, Yvette H. van Beurden

    One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this study was to externally validate published clinical prediction tools for rCDI. The validation cohort consisted of 129 patients, diagnosed with CDI between 2018 and 2020. rCDI risk scores were calculated for each individual patient in the validation cohort using the scoring tools described in the derivation studies. Per score value, we compared the average predicted risk of rCDI with the observed number of rCDI cases. Discrimination was assessed by calculating the area under the receiver operating characteristic curve (AUC). Two prediction tools were selected for validation (Cobo 2018 and Larrainzar-Coghen 2016). The two derivation studies used different definitions for rCDI. Using Cobo’s definition, rCDI occurred in 34 patients (26%) of the validation cohort: using the definition of Larrainzar-Coghen, we observed 19 recurrences (15%). The performance of both prediction tools was poor when applied to our validation cohort. The estimated AUC was 0.43 [95% confidence interval (CI); 0.32–0.54] for Cobo’s tool and 0.42 (95% CI; 0.28–0.56) for Larrainzar-Coghen’s tool. Performance of both prediction tools was disappointing in the external validation cohort. Currently identified clinical risk factors may not be sufficient for accurate prediction of rCDI.


  • Open Access

    Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samples

    by Tessel Meike van Rossen, Joffrey van Prehn, Alex G. Koek, Marcel Jonges, Robin van Houdt, Rosa van Mansfeld, Ed J. Kuijper, Christina M.J.E. Vandenbroucke-Grauls, Andries E. Budding

    Background: Clostridioides difficile is the most common cause of nosocomial diarrhea. Ribotyping of cultured strains by a PCR-based test is used to study potential transmission between patients. We aimed to develop a rapid test that can be applied directly on fecal samples for simultaneous detection and ribotyping of C. difficile, as well as detection of toxin genes.Methods: We developed a highly specific and sensitive primer set for simultaneous detection and ribotyping of C. difficile directly on total fecal DNA. Toxin genes were detected with primers adapted from Persson et al. (CMI, 2008). Our study set comprised 130 fecal samples: 65 samples with positive qPCR for C. difficile toxin A/B genes and 65 C. difficile qPCR negative samples. PCR products were analyzed by capillary gel electrophoresis. Results: Ribosomal DNA fragment peak profiles and toxin genes were detected in all 65 C. difficile positive fecal samples and in none of the 65 C. difficile negative samples. The 65 samples were assigned to 27 ribotypes by the Dutch reference laboratory. Our peak profiles corresponded to these ribotypes, except for two samples. During a C. difficile outbreak, patients were correctly allocated to the outbreak-cluster based on the results of direct fecal ribotyping, before C. difficile isolates were cultured and conventionally typed.Conclusion: C. difficile ribotyping directly on fecal DNA is feasible, with sensitivity and specificity comparable to that of diagnostic toxin gene qPCR and with ribotype assignment similar to that obtained by conventional typing on DNA from cultured isolates. This supports simultaneous diagnosis and typing to recognize an outbreak.